Analysts are on the Bearish side about Celgene Corporation (NASDAQ:CELG) this week.

September 8, 2018 - By Victoria Pittman

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.79 in Q1 2018. Its down 0.04, from 0.83 in 2017Q4. It turned negative, as 120 investors sold Celgene Corporation shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported.
Perigon Wealth Limited Liability Co has 36,083 shares for 1.19% of their portfolio. Cetera Advsr Ltd Company reported 5,321 shares. Allsquare Wealth Management Ltd Limited Liability Company reported 0.16% of its portfolio in Celgene Corporation (NASDAQ:CELG). Wolverine Asset Mgmt Ltd accumulated 0.01% or 9,355 shares. Gofen & Glossberg Limited Liability Company Il holds 1.37% or 409,003 shares. Quinn Opportunity Prtnrs Ltd Llc owns 5,000 shares or 0.06% of their US portfolio. Roundview Capital Ltd Liability has 7,005 shares for 0.18% of their portfolio. Exane Derivatives accumulated 4,430 shares. 54.47M are owned by Blackrock Inc. Employees Retirement Association Of Colorado has invested 0.08% in Celgene Corporation (NASDAQ:CELG). Comm Commercial Bank stated it has 164,977 shares. Charter holds 0.07% or 6,558 shares. Cohen Klingenstein Limited Liability Corp holds 13,240 shares or 0.17% of its portfolio. Cape Cod Five Cents Financial Bank accumulated 2,485 shares or 0.03% of the stock. Moreover, Kidder Stephen W has 0.44% invested in Celgene Corporation (NASDAQ:CELG).

Since March 12, 2018, it had 1 buy, and 2 sales for $2.33 million activity. 13,000 Celgene Corporation (NASDAQ:CELG) shares with value of $1.02 million were sold by CASEY MICHAEL D. The insider Alles Mark J bought $99,784.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 10 analysts covering Celgene (NASDAQ:CELG), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Celgene had 15 analyst reports since March 21, 2018 according to SRatingsIntel. As per Wednesday, May 23, the company rating was upgraded by Bernstein. The firm has “Buy” rating given on Monday, May 7 by Leerink Swann. Oppenheimer maintained Celgene Corporation (NASDAQ:CELG) on Friday, May 25 with “Buy” rating. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, April 13 report. The rating was downgraded by Argus Research on Wednesday, May 23 to “Hold”. The rating was maintained by Morgan Stanley on Friday, July 27 with “Equal-Weight”. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, May 7. The stock has “Buy” rating by RBC Capital Markets on Wednesday, April 4. As per Monday, May 7, the company rating was downgraded by RBC Capital Markets. The stock of Celgene Corporation (NASDAQ:CELG) has “Overweight” rating given on Wednesday, March 21 by JP Morgan. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

27/07/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $91 New Target: $93 Maintain
13/07/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $90 New Target: $91 Maintain
18/06/2018 Broker: Standpoint Research Old Rating: Hold New Rating: Buy Upgrade
31/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $112.0000 Maintain
25/05/2018 Broker: Oppenheimer Rating: Buy New Target: $163.0000 Maintain
23/05/2018 Broker: Argus Research Old Rating: Buy New Rating: Hold Downgrade
23/05/2018 Broker: Bernstein Rating: Buy Upgrade
07/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $93 New Target: $90 Maintain
07/05/2018 Broker: Leerink Swann Rating: Buy New Target: $115.0000 Maintain
07/05/2018 Broker: RBC Capital Markets Old Rating: Top Pick New Rating: Outperform Old Target: $120 New Target: $118 Downgrade

The stock increased 0.63% or $0.57 during the last trading session, reaching $90.46. About 3.14M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since September 8, 2017 and is downtrending. It has underperformed by 45.22% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $63.63 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 25.16 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: which released: “One Year Later: Lessons Learned In CAR-T” on August 14, 2018, also with their article: “Trade of the Day: Celgene Is Coiling Up for a Rally” published on August 29, 2018, published: “Celgene Corporation (CELG) CEO Mark Alles on Citi’s 13th Annual Biotech Conference (Transcript)” on September 06, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: and their article: “Celgene’s CEO Wants to Make the Biotech’s Best-Selling Drug Obsolete — Here’s Why That’s Great for Investors” published on September 07, 2018 as well as‘s news article titled: “Is The Bottom In For Celgene?” with publication date: August 14, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.